Bioventus Earnings Estimate

BVS Stock  USD 9.61  0.46  4.57%   
The next projected EPS of Bioventus is estimated to be 0.0228 with future projections ranging from a low of -0.02 to a high of 0.0585. Bioventus' most recent 12-month trailing earnings per share (EPS TTM) is at -0.52. Please be aware that the consensus of earnings estimates for Bioventus is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Bioventus is projected to generate 0.0228 in earnings per share on the 31st of March 2025. Bioventus earnings estimates show analyst consensus about projected Bioventus EPS (Earning Per Share). It derives the highest and the lowest estimates based on Bioventus' historical volatility. Many public companies, such as Bioventus, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Bioventus Revenue Breakdown by Earning Segment

By analyzing Bioventus' earnings estimates, investors can diagnose different trends across Bioventus' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit Margin is likely to gain to 0.76 in 2025, whereas Gross Profit is likely to drop slightly above 303.8 M in 2025.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.

Bioventus Earnings Estimation Breakdown

The calculation of Bioventus' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Bioventus is estimated to be 0.0228 with the future projection ranging from a low of -0.02 to a high of 0.0585. Please be aware that this consensus of annual earnings estimates for Bioventus is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.15
-0.02
Lowest
Expected EPS
0.0228
0.06
Highest

Bioventus Earnings Projection Consensus

Suppose the current estimates of Bioventus' value are higher than the current market price of the Bioventus stock. In this case, investors may conclude that Bioventus is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Bioventus' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2025Current EPS (TTM)
320.16%
0.15
0.0228
-0.52

Bioventus Earnings History

Earnings estimate consensus by Bioventus analysts from Wall Street is used by the market to judge Bioventus' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Bioventus' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Bioventus Quarterly Gross Profit

102.66 Million

Retained Earnings is likely to gain to about (337.3 M) in 2025. Retained Earnings Total Equity is likely to drop to about (6.2 M) in 2025 Net Income Applicable To Common Shares is likely to gain to about 23.4 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 64.4 M in 2025.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bioventus' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
5.369.5513.74
Details
Intrinsic
Valuation
LowRealHigh
8.1912.3816.57
Details
Naive
Forecast
LowNextHigh
6.0610.2514.43
Details
3 Analysts
Consensus
LowTargetHigh
13.6515.0016.65
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Bioventus assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Bioventus. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Bioventus' stock price in the short term.

Bioventus Earnings per Share Projection vs Actual

Actual Earning per Share of Bioventus refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Bioventus predict the company's earnings will be in the future. The higher the earnings per share of Bioventus, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Bioventus Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Bioventus, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Bioventus should always be considered in relation to other companies to make a more educated investment decision.

Bioventus Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Bioventus' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-03-10
2024-12-310.0850.150.06576 
2024-11-05
2024-09-300.030.060.03100 
2024-08-06
2024-06-300.070.190.12171 
2024-05-07
2024-03-31-0.070.070.14200 
2024-03-12
2023-12-310.020.070.05250 
2023-11-07
2023-09-30-0.020.050.07350 
2023-08-08
2023-06-300.030.140.11366 
2023-05-16
2023-03-31-0.15-0.26-0.1173 
2023-03-31
2022-12-310.05-0.06-0.11220 
2022-11-08
2022-09-300.120.08-0.0433 
2022-08-11
2022-06-300.160.1-0.0637 
2022-05-10
2022-03-310.050.04-0.0120 
2022-03-10
2021-12-310.180.260.0844 
2021-11-09
2021-09-300.140.250.1178 
2021-08-10
2021-06-300.140.160.0214 
2021-05-12
2021-03-310.10.150.0550 
2021-03-25
2020-12-310.232.322.09908 
2020-10-06
2020-09-3000.020.02

About Bioventus Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Bioventus earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Bioventus estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Bioventus fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-355.1 M-337.3 M
Retained Earnings Total Equity-5.9 M-6.2 M
Earnings Yield(0.07)(0.08)
Price Earnings Ratio(13.97)(14.67)
Price Earnings To Growth Ratio 0.20  0.19 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bioventus Stock Analysis

When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.